Study of Protein Linked to Alzheimer's Gives Hope for Therapeutic | GenomeWeb

In an ongoing quest to find how exactly amyloid b protein is made from the amyloid precursor protein, researchers led by David Kang at the University of California, San Diego, have made a big step in the right direction. In a study published recently in the Journal of Biological Chemistry, Kang's team found that Ran-binding protein 9, RanBP9, plays a role by conjugating with another protein to form a scaffold that initiates the enzymatic cleavage of APP to Ab. The role of RanBP9, says Kang, could make it a possible new therapeutic target for Alzheimer's disease.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.